High Response Rates With Gene Therapies for BCG-Unresponsive Bladder Cancer

MedPage Today) — SAN ANTONIO — More than 70% of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) achieved complete responses to a novel gene therapy, a small preliminary trial showed.
Across a range of doses, 16 of…

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button